MUC16 and idiopathic pulmonary fibrosis: We conducted an exploratory, longitudinal study with up to 24 months of serial measurements of seven IPF serum biomarkers, including KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in a cohort of IPF patients qualified for anti-fibrotic therapy at a single reference center.